The Latin America, Middle East and Africa Sepsis Diagnostics Market would witness market growth of 14.0% CAGR during the forecast period (2022-2028).
Children account for a significant proportion of the total instances of sepsis diagnosed each year, leading to a considerable number of deaths annually, the majority of which might be avoided with early identification and adequate clinical therapy. Diarrheal illnesses or respiratory illnesses are frequently the cause of these deaths. Obstetric infections, such as infections after an abortion or infections after a caesarean section, are the third leading cause of maternal death.
Biosensors that monitor biological or chemical interactions are frequently used to diagnose sepsis. Biosensors are devices that produce a signal proportional to analyses concentrations in biological samples. Biosensors are made up of a variety of components, including analyses, bio receptors, signal transducers, and display panels. Biosensors can identify low signals in a range of biological fluids using a minimal number of samples. Nanotechnology-based biosensors offer a revolutionary diagnostic technique that improves biomarker sensitivity and processing speed without requiring professional abilities. Biomarkers are frequently used in sepsis management for diagnostic, monitoring, prognostic, surrogate, and stratification purposes. PCT, CRP, and Interleukin-6 are three biomarkers that have proven useful in the clinical diagnosis of sepsis.
There is a significant prevalence of sepsis in Africa. According to the African Sepsis Alliance, in Africa, at least 2 million people die from sepsis each year. In addition, these figures, however, are likely to be grossly underestimated, because sepsis is rarely identified, recognized, or recorded as a cause of death in Africa. Sepsis is the third leading cause of maternal death, contributing to 11% of all maternal fatalities. Africa is predicted to have a greater incidence of maternal deaths due to sepsis, which accounts for two-thirds of infant deaths. Moreover, sepsis is a major public health issue that affects people in this region.
In well-resourced healthcare systems, there is substantial research into techniques to improve survival. Furthermore, since its beginning, the Enduring Sepsis Campaign has succeeded in elevating the profile of sepsis by raising awareness and offering evidence-based recommendations for optimal management, education, and performance improvement.
The Brazil market dominated the LAMEA Sepsis Diagnostics Market by Country in 2021, and would continue to be a dominant market till 2018; thereby, achieving a market value of $20.7 million by 2028. The Argentina market is anticipated to grow at a CAGR of 14.6% during (2022 - 2028). Additionally, The UAE market would experience a CAGR of 13.7% during (2022 - 2028).
Based on Method, the market is segmented into Conventional and Automated. Based on Test Type, the market is segmented into Laboratory Tests and Point-of-Care Tests. Based on Pathogen, the market is segmented into Bacterial Sepsis, Fungal Sepsis, Viral Sepsis, and Others. Based on Product, the market is segmented into Blood Culture Media, Assays & Reagents, Instruments, and Software. Based on End-User, the market is segmented into Hospitals & specialty clinics, Pathology & Reference Laboratories, and Research Laboratories & Academic Institutes. Based on Technology, the market is segmented into Blood Culture, Immunoassays, Molecular Diagnostics, Flow Cytometry, Microfluidics, and Biomarkers. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
Free Valuable Insights: The Global Sepsis Diagnostics MarketMarket is Predict to reach $879.5 Million by 2028, at a CAGR of 8.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include BioMérieux S.A., F. Hoffmann-La Roche Ltd., Becton, Dickinson and Company, Abbott Laboratories, Thermo Fisher Scientific, Inc., DiaSorin S.p.A., Bruker Corporation, Siemens Healthineers AG, Danaher Corporation, and Quidel Corporation.
By Method
By Test Type
By Pathogen
By Product
By End-User
By Technology
By Country
Unique Offerings Our team of dedicated experts can provide you with attractive expansion opportunities for your business.
